Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: GX-I7
Drug: Cyclophosphamide

First Posted Date: 2018-11-07

Last Posted Date: 2020-05-14

Lead Sponsor: Genexine, Inc.

Target Recruit Count: 24

Registration Number: NCT03733587

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of

Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Refractory Multiple Myeloma

Interventions: Drug: MLN9708
Drug: Pomalidomide 4 MG Oral Capsule
Drug: Dexamethasone
Drug: Cyclophosphamide

First Posted Date: 2018-11-06

Last Posted Date: 2023-10-12

Lead Sponsor: GWT-TUD GmbH

Target Recruit Count: 82

Registration Number: NCT03731832

Locations: 🇩🇪
Kliniken Ostalb Stauferklinikum Schwäbisch Gmünd, Mutlangen, Germany
🇩🇪
phase drei Hämato-Onkologischer Studienkreis am Klinikum Aschaffenburg, Aschaffenburg, Germany
🇩🇪
Sozialstiftung Bamberg / Klinik am Bruderwald, Zentrum für Innere Medizin, Med. Klinik V, Hämatologie und internistische Onkologie, Bamberg, Germany

and more 8 locations

A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Placebo
Drug: Atezolizumab
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Paclitaxel
Drug: Trastuzumab
Drug: Pertuzumab
Drug: Trastuzumab Emtansine

First Posted Date: 2018-11-01

Last Posted Date: 2024-11-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 454

Registration Number: NCT03726879

Locations: 🇺🇸
Tennessee Oncology - Nashville, Nashville, Tennessee, United States
🇺🇸
HCA Midwest Division, Kansas City, Missouri, United States
🇺🇸
New York University Medical Center PRIME; NYU Langone Medical Center, New York, New York, United States

and more 73 locations

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

Phase 1

Recruiting

Conditions: Osteosarcoma
Neuroblastoma

Interventions: Biological: iC9.GD2.CAR.IL-15 T-cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2018-10-26

Last Posted Date: 2024-10-24

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 18

Registration Number: NCT03721068

Locations: 🇺🇸
Emory - Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

Early Phase 1

Recruiting

Conditions: NK-Cell Leukemia
Peripheral T Cell Lymphoma
NK-Cell Lymphoma

Interventions: Drug: pralatraxate,
Drug: Methotrexate
Drug: Ifosfamide
Drug: cyclophosphamide
Drug: Dexamethasone
Drug: Doxorubicin
Drug: Etoposide
Drug: Prednisone
Drug: Brentuximab Vedotin
Drug: calaspargase pegol

First Posted Date: 2018-10-25

Last Posted Date: 2023-10-26

Lead Sponsor: New York Medical College

Target Recruit Count: 40

Registration Number: NCT03719105

Locations: 🇺🇸
Children's Hospital Orange County, Orange, California, United States
🇺🇸
Helen De Vos, Grand Rapids, Michigan, United States
🇺🇸
University of Alabama, Birmingham, Alabama, United States

and more 3 locations

Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma

Phase 1

Conditions: Refractory or Relapsed Multiple Myeloma

Interventions: Genetic: CAR-BCMA T cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2018-10-23

Last Posted Date: 2020-10-08

Lead Sponsor: First Affiliated Hospital of Zhejiang University

Target Recruit Count: 11

Registration Number: NCT03716856

Locations: 🇨🇳
First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China

2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies

Phase 2

Active, not recruiting

Conditions: Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Radiation: Total-Body Irradiation
Procedure: Donor Lymphocyte Infusion
Drug: Cyclophosphamide
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Tacrolimus
Drug: Mycophenolate Mofetil

First Posted Date: 2018-10-19

Last Posted Date: 2025-01-03

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 10

Registration Number: NCT03712878

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

Phase 1

Recruiting

Conditions: Refractory Plasma Cell Myeloma
Recurrent Plasma Cell Myeloma

Interventions: Procedure: CS1-CAR T Therapy
Drug: Cyclophosphamide
Drug: Fludarabine
Procedure: Leukapheresis

First Posted Date: 2018-10-18

Last Posted Date: 2024-12-04

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 30

Registration Number: NCT03710421

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Mantle Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Drug: Ibrutinib
Drug: Methotrexate
Biological: Rituximab
Drug: Venetoclax
Drug: Vincristine Sulfate

First Posted Date: 2018-10-18

Last Posted Date: 2024-11-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 51

Registration Number: NCT03710772

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Phase 1

Active, not recruiting

Conditions: Rhabdoid Tumor
Solid Tumors
Medulloblastoma
Ewing Sarcoma
Rhabdomyosarcoma
Diffuse Intrinsic Pontine Glioma
Neuroblastoma

Interventions: Drug: Palbociclib
Drug: Temozolomide
Drug: Cyclophosphamide
Drug: Irinotecan
Drug: Topotecan

First Posted Date: 2018-10-17

Last Posted Date: 2024-08-09

Lead Sponsor: Pfizer

Target Recruit Count: 128

Registration Number: NCT03709680

Locations: 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 134 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy